Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine

Trial Profile

Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccine

Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs ETBX- 071 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 26 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 31 Jul 2018 to 1 Aug 2018.
    • 25 Jul 2018 Planned primary completion date changed from 1 Jun 2021 to 1 May 2021.
    • 25 Jul 2018 Planned initiation date (estimated date for recruitment of the first subject) changed from 23 Jul 2018 to 31 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top